Euroespes SA
MAD:EEP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.3), the stock would be worth €0.54 (59% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.8 | €0.34 |
0%
|
| 3-Year Average | 1.3 | €0.54 |
+59%
|
| 5-Year Average | 1.3 | €0.54 |
+59%
|
| Industry Average | 2.8 | €1.22 |
+260%
|
| Country Average | 2 | €0.84 |
+148%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| ES |
|
Euroespes SA
MAD:EEP
|
3.9m EUR | 0.8 | -3.4 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 142.4 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.6B USD | 3.4 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
125.4B USD | 2.4 | 34 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 6.8 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 3.8 | 15.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 3.8 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.7 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.4B USD | 11.9 | 47.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 4.3 | 20.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD | -1 104.7 | 30 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 1.4 |
| Median | 2 |
| 70th Percentile | 2.9 |
| Max | 56.2 |
Other Multiples
Euroespes SA
Glance View
EuroEspes SA engages in the provision of biomedical services. The company is headquartered in Bergondo, La Coruna. The company went IPO on 2012-06-21. The firm operates a medical center, which focuses on the prevention, diagnosis and treatment of central nervous system disorders, such as Alzheimer and Parkinson, and other common diseases. The Company’s medical offer includes personalized treatment plans, genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis and nursing services, among others. In addition, it provides pharmacogenetics services and Human Identification Genetics card, which identifies user's deoxyribonucleic acid (DNA) profile. The firm operates through a number of subsidiaries, such as in Euroespes Biotecnologia SA, Distribuidora de Productos SL and Ebiotec Pharma SL.
